Innovations in Drug Discovery: Trends Redefining Pharma R&D Kumar Jeetendra | May 6, 2026 Can gene editing be used as a life-saving treatment? Could antiviral drugs that target human proteins be more effective than those than target the viruses themselves? The constant evolution of drug discovery is one of the most exciting aspects of modern medicine, and new research is leading to breakthroughs in precision medicine, cancer immunotherapy, neurodegenerative …
Cipla, SBP Group Sign Exclusive License for HER2 Bispecific ADC Kumar Jeetendra | September 7, 2026 Cipla Limited (BSE: 500087; NSE: CIPLA) (“Cipla”) and Sino Biopharmaceutical Limited (HKEX: 1177) (“SBP Group”) today announced that SBP Group’s subsidiary, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (“CTTQ”), has entered into an exclusive license and supply agreement with Cipla for Rolditamig Deuderuxtecan, also known as TQB2102, a potential best-in-class HER2 bispecific antibody-drug conjugate (“ADC”). …
